Antiphospholipid antibodies and atherosclerosis

Lupus

Volumn 5, Issue 5, 1996, Pages 442-447

  Vaarala, O ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Oxidized low density lipoprotein; Prothrombin; Thrombosis; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; LOW DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONFERENCE PAPER; IMMUNOPATHOGENESIS; PRIORITY JOURNAL; VEIN THROMBOSIS;

EID: 0029830512     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339600500522     Document Type: Conference Paper

References (48)

1. Roubey RA. Antibodies to phospholipid-binding plasma proteins. A new view of lupus anticoagulants and other 'antiphospholipid' autoantibodies. Blood 1994; 84: 2854-2867.
2. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
3. Palinski W et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modifications of low density lipoprotein. Arteriosclerosis 1990; 10: 325-335.
4. Steinbrecher UP et al. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 83: 3883-3887.
5. Parums DV, Brown DL, Mitchison MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in human periaortitis. Arch Pathol Lab Med 1990; 114: 383-387.
6. Viard JP, Amoura Z, Bach JF. Association of anti-beta2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186.
7. Martinuzzo ME, Forastiero RR, Carreras LO. Anti β2-glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995; 89: 397-402.
8. Cabiedes J, Cabral AR, Alarcn-Segovia. Clinical manifestations of antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-β2-glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
9. Puurnen M et al. Antibodies to phospholipid-binding proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immuno Immunopath 1996; 80: 16-22.
10. Matsuura E et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992; 148: 3885-3891.
11. Hunt JE et al. A phospholipid beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81.
12. Salonen JT et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
13. Maggi E et al. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994; 14: 1892-1899.
14. Puurunen M et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609.
15. Vaarala O et al. Crossreaction between antibodies to oxidised lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.
16. Vaarala O et al. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol 1996; 104: 269-274.
17. Mizutani H et al. Monoclonal anticardiolipin autoantibodies established for the (New Zealand White × BXSB)F1 mouse model of antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995; 38: 1382-1388.
18. Matsuura E, Katahira T, Igarashi Y, Koike T. β2-glycoprotein I bound to oxidatively modified lipoproteins could be targeted by anticardiolipin antibodies. Lupus 1994; 3: 314.
19. Jonsson H, Nived O, Sturfelt G. Outcome is systemic lupus erythematosus: a prospective study of patients form a defined population. Medicine (Baltimore) 1989; 68: 141-150.
20. Asherson RA, Mackay JR, Harris EN. Myocardial infarction in a young man with systemic lupus erythematosus, deep vein thrombosis, and antibodies to phospholipid. Br Heart J 1986; 56: 190-193.
21. Maaravi Y, Raz E, Gilon D, Rubinow A. Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young woman with systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 853-855.
22. Baker WF, Bick RL. Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost 1994; 20: 27-34.
23. Vaarala O et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27.
24. Aho K et al. Antibodies binding to anionic phospholipids but not to oxidized low-density lipoprotein are associated with thrombosis in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1996 (in press).
25. Fogelman AM et al. Malondialdehyde alteration of low density lipoprotein leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 1980; 77. 2214-2218.
26. Haberland ME, Olch CL, Fogelman AM. Role of lysines in mediating interaction of modified low density lipoprotein with the scavenger receptor of human monocyte macrophages. J Biol Chem 1984; 259: 11305-11311.
27. Palinski W et al. Low-density lipoprotein undergoes oxidative modifications in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-1376.
28. Yl-Herttuala S et al. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 85: 1086-1095.
29. Kabakov AE et al. The atherogenic effect of lupus sera: Systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultures smooth muscle cells for human aorta. Clin Immunol Immunopath 1992; 63: 214-220.
30. Manoussakis MN et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987; 69: 557-565.
31. Jonasson L et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-138.
32. Frostergård J et al. Induction of T-cell activation by oxidized low density lipoprotein. Arteriosclerosis Thrombosis 1992; 12: 461-467.
33. Huang You-Peng, Perrin LH, Miescher PA, Zubler RH. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988; 141: 827-833.
34. Arvieux J, Roussel B, Ponard D, Colomb MG. IgG2 subclass restriction of anti-beta 2 glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-315.
35. Stevens TL et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988; 334: 255-258.
36. Saikku P et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986.
37. Kuo CC et al. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci USA 1995; 92: 6911-6914.
38. Vaarala O. Binding profiles of anticardiolipin antibodies in sera from patients with SLE and infectious diseases. J Autoimmun 1991; 4: 819-830.
39. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462.
40. Wu JR, Lentz BR. Phospholipid-specific conformational changes in human prothrombin upon binding to procoagulant acidic lipid membranes. Thromb Haemost 1994; 71: 596-604.
41. Lassila R et al. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-1742.
42. Kienast J et al. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atheriosclerosis. Thromb Haemost 1994; 72: 550-553.
43. Ginsberg JS et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-2963.
44. Vaarala O et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-459.
45. Mussoni L et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27.
46. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atheroscleroiss. Nature 1989; 339: 303-305.
47. Miles LA et al. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature 1989; 339: 301-303.
48. Puurunen M et al. Autoantibodies against plasma phospholipid-binding proteins and risk of myocardial infarction (Abstract submitted to 7th International Symposium on antiphospholipid antibodies, New Orleans, 1996).